Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lobbestael, E ^a   Civiero, L ^b   De Wit, T ^a   Taymans, J M ^c   Greggio, E ^b   Baekelandt, V ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF PADOVA   (Italy)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988569312     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33897     Document Type: Article

References (60)

1. Taymans, J. M. & Greggio, E. LRRK2 kinase Inhibition as a therapeutic strategy for Parkinson's Disease, where do we stand? Curr Neuropharmacol. 14, 214-225 (2016).
2. Gasser, T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 11, e22 (2009).
3. Paisan-Ruiz, C. LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat. 30, 1153-1160 (2009).
4. Lill, C. M. et al. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genet. 8, e1002548 (2012).
5. Ross, O. A. et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10, 898-908 (2011).
6. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 41, 1303-1307 (2009).
7. Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 41, 1308-1312 (2009).
8. Greggio, E. & Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 1 (2009).
9. Reynolds, A., Doggett, E. A., Riddle, S. M., Lebakken, C. S. & Nichols, R. J. LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Frontiers in molecular neuroscience. 7, 54 (2014).
10. Sheng, Z. et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Science translational medicine. 4, 164ra161 (2012).
11. Greggio, E. et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 23, 329-341 (2006).
12. Lee, B. D. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 16, 998-1000 (2010).
13. Smith, W. W. et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 9, 1231-1233 (2006).
14. Cooper, O. et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Science translational medicine. 4, 141ra190 (2012).
15. Yao, C. et al. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet. 22, 328-344 (2013).
16. Deng, X., Choi, H. G., Buhrlage, S. J. & Gray, N. S. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011). Expert opinion on therapeutic patents. 22, 1415-1426 (2012).
17. Kethiri, R. R. & Bakthavatchalam, R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013). Expert opinion on therapeutic patents. 24, 745-757 (2014).
18. Gloeckner, C. J. et al. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res. 9, 1738-1745 (2010).
19. Nichols, R. J. et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J. 430, 393-404 (2010).
20. West, A. B. et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet. 16, 223-232 (2007).
21. Chia, R. et al. Phosphorylation of LRRK2 by casein kinase 1alpha regulates trans-Golgi clustering via differential interaction with ARHGEF7. Nat Commun. 5, 5827 (2014).
22. Doggett, E. A., Zhao, J., Mork, C. N., Hu, D. & Nichols, R. J. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J Neurochem. 120, 37-45 (2011).
23. Dzamko, N. et al. The IkappaB Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling. PLoS ONE. 7, e39132 (2012).
24. Ito, G., Fujimoto, T., Kamikawaji, S., Kuwahara, T. & Iwatsubo, T. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. PLoS ONE. 9, e97988 (2014).
25. Li, X. et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS ONE. 6, e17153 (2011).
26. Lobbestael, E., Baekelandt, V. & Taymans, J. M. Phosphorylation of LRRK2: from kinase to substrate. Biochem Soc Trans. 40, 1102-1110 (2012).
27. Muda, K. et al. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl Acad Sci USA. 111, E34-E43 (2014).
28. Choi, H. G. et al. Brain Penetrant LRRK2 Inhibitor. ACS medicinal chemistry letters. 3, 658-662 (2012).
29. Dzamko, N. et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 430, 405-413 (2010).
30. Vancraenenbroeck, R. et al. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Frontiers in molecular neuroscience. 7, 51 (2014).
31. Hermanson, S. B. et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation. PLoS ONE. 7, e43580 (2012).
32. Delbroek, L. et al. Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. Journal of pharmaceutical and biomedical analysis. 76, 49-58 (2013).
33. Lobbestael, E. et al. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J. 456, 119-128 (2013).
34. Taymans, J. M. & Baekelandt, V. Phosphatases of alpha-synuclein, LRRK2, and tau: important players in the phosphorylationdependent pathology of Parkinsonism. Frontiers in genetics. 5, 382 (2014).
35. Zhao, J., Molitor, T. P., Langston, J. W. & Nichols, R. J. LRRK2 Dephosphorylation increases its ubiquitination. Biochem J (2015).
36. Fuji, R. N. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science translational medicine. 7, 273ra215 (2015).
37. Herzig, M. C. et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 20, 4209-4223 (2011).
38. Skibinski, G., Nakamura, K., Cookson, M. R. & Finkbeiner, S. Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies. J Neurosci. 34, 418-433 (2014).
39. Fell, M. J. et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 355, 397-409 (2015).
40. Baptista, M. A. et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS ONE. 8, e80705 (2013).
41. Miklavc, P. et al. Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. PLoS ONE. 9, e84926 (2014).
42. Daher, J. P., Volpicelli-Daley, L. A., Blackburn, J. P., Moehle, M. S. & West, A. B. Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci USA 111, 9289-9294 (2014).
43. Lin, X. et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron. 64, 807-827 (2009).
44. Henderson, J. L. et al. Discovery and Preclinical Profiling of 3[4-(Morpholin-4-yl)7Hpyrrolo[2, 3d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor. Journal of medicinal chemistry (2015).
45. Reith, A. D. et al. GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorganic & Medicinal Chemistry Letters. 22, 5625-5629 (2012).
46. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 7, 203-205 (2011).
47. Ramsden, N. et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's diseaserelated toxicity in human neurons. ACS Chem Biol. 6, 1021-1028 (2011).
48. Nichols, R. J. et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 424, 47-60 (2009).
49. Reith, A. D. et al. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett. 22, 5625-5629 (2012).
50. Zhang, J., Deng, X., Choi, H. G., Alessi, D. R. & Gray, N. S. Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett. 22, 1864-1869 (2012).
51. Choi, H. G. et al. Brain Penetrant LRRK2 Inhibitor. ACS medicinal chemistry letters. 3, 658-662 (2012).
52. Greene, I. D. et al. Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation. J Neurosci Res. 92, 506-516 (2014).
53. Ko, H. S. et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA 106, 2897-2902 (2009).
54. Wang, L. et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci. 28, 3384-3391 (2008).
55. West, A. B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102, 16842-16847 (2005).
56. Fuji, R. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science translational medicine. 7, 273ra215 (2015).
57. Herzig, M. C. et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Human molecular genetics. 20, 4209-4223 (2011).
58. Tong, Y. et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Molecular neurodegeneration. 7, 2 (2012).
59. Tong, Y. et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alphasynuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America. 107, 9879-9884 (2010).
60. Daher, J. P. L. et al. LRRK2 Pharmacological Inhibition Abates ?-Synuclein Induced Neurodegeneration. Journal of Biological Chemistry. jbc. M115. 660001 (2015).